5-Year Outcomes Comparing Surgical Versus Transcatheter Aortic Valve Replacement in Patients With Chronic Kidney Disease

Santiago Garcia*, Robert J. Cubeddu, Rebecca T. Hahn, Julien Ternacle, Samir R. Kapadia, Susheel K. Kodali, Vinod H. Thourani, Wael A. Jaber, Craig R. Asher, Sammy Elmariah, Raj Makkar, John G. Webb, Howard C. Herrmann, Michael Lu, Chandan M. Devireddy, S. Chris Malaisrie, Craig R. Smith, Michael J. Mack, Paul Sorajja, João L. CavalcanteMario Goessl, Gautam R. Shroff, Martin B. Leon, Philippe Pibarot

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Objectives: The aim of this study was to compare 5-year cardiovascular, renal, and bioprosthetic valve durability outcomes in patients with severe aortic stenosis (AS) and chronic kidney disease (CKD) undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Background: Patients with severe AS and CKD undergoing TAVR or SAVR are a challenging, understudied clinical subset. Methods: Intermediate-risk patients with moderate to severe CKD (estimated glomerular filtration rate <60 mL/min/m2) from the PARTNER (Placement of Aortic Transcatheter Valve) 2A trial (patients randomly assigned to SAPIEN XT TAVR or SAVR) and SAPIEN 3 Intermediate Risk Registry were pooled. The composite primary outcome of death, stroke, rehospitalization, and new hemodialysis was evaluated using Cox regression analysis. Patients with and without perioperative acute kidney injury (AKI) were followed through 5 years. A core laboratory–adjudicated analysis of structural valve deterioration and bioprosthetic valve failure was also performed. Results: The study population included 1,045 TAVR patients (512 SAPIEN XT, 533 SAPIEN 3) and 479 SAVR patients. At 5 years, SAVR was better than SAPIEN XT TAVR (52.8% vs 68.0%; P = 0.04) but similar to SAPIEN 3 TAVR (52.8% vs 58.7%; P = 0.89). Perioperative AKI was more common after SAVR than TAVR (26.3% vs 10.3%; P < 0.001) and was independently associated with long-term outcomes. Compared with SAVR, bioprosthetic valve failure and stage 2 or 3 structural valve deterioration were significantly greater for SAPIEN XT TAVR (P < 0.05) but not for SAPIEN 3 TAVR. Conclusions: In intermediate-risk patients with AS and CKD, SAPIEN 3 TAVR and SAVR were associated with a similar risk for the primary endpoint at 5 years. AKI was more common after SAVR than TAVR, and SAPIEN 3 valve durability was comparable with that of surgical bioprostheses.

Original languageEnglish (US)
Pages (from-to)1995-2005
Number of pages11
JournalJACC: Cardiovascular Interventions
Issue number18
StatePublished - Sep 27 2021


  • acute kidney injury
  • bioprosthetic valve failure
  • hemodialysis
  • intermediate risk
  • structural valve deterioration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of '5-Year Outcomes Comparing Surgical Versus Transcatheter Aortic Valve Replacement in Patients With Chronic Kidney Disease'. Together they form a unique fingerprint.

Cite this